



Press release

24 September 2009

## Galapagos announces expanded drug discovery collaboration with Schering-Plough

Mechelen, Belgium and Saffron Walden, UK; 24 September 2009 – [Galapagos NV](#) (Euronext: GLPG) announces today that its service division, [BioFocus DPI](#), has initiated a drug discovery collaboration with Schering-Plough Research Institute (SPRI). Under the terms of the agreement, BioFocus DPI will perform medicinal chemistry with supporting biology and ADME/PK services for multiple Schering-Plough drug discovery projects. Total contract value for Galapagos is €2.8 M over a one year period.

Building on a collaboration established in May 2009 and expanded this month, BioFocus DPI scientists will work with two of SPRI's European sites on these drug discovery projects.

"We are pleased to build on our collaborative relationship with SPRI, which has evolved into one of the larger for BioFocus DPI this year with over 20 research staff currently engaged," said Onno van de Stolpe, CEO of Galapagos. "BioFocus DPI has proven resilient in securing large collaborations with strong partners, amidst consolidation and reorganization in the pharma industry."

### About Galapagos and BioFocus DPI

[Galapagos](#) (Euronext: GLPG; OTC: GLPYY) is a drug discovery and development company with small molecule programs in bone and joint diseases, bone metastasis, cachexia, anti-infectives and metabolic diseases. Its division [BioFocus DPI](#) offers a full suite of target-to-drug discovery products and services to pharmaceutical and biotech companies as well as not-for-profit organizations, encompassing target discovery and validation, screening and drug discovery through to delivery of pre-clinical candidates. BioFocus DPI also provides adenoviral reagents for rapid identification and validation of novel drug targets, compound libraries for drug screening as well as ADMET products to select compounds. Galapagos currently employs 495 people and operates facilities in six countries, with global headquarters in Mechelen, Belgium. More info at [www.glpq.com](http://www.glpq.com) and [www.biofocusdpi.com](http://www.biofocusdpi.com).

### CONTACTS

Galapagos NV  
Onno van de Stolpe, CEO  
Tel: +31 6 2909 8028  
[ir@glpg.com](mailto:ir@glpg.com)

*This release may contain forward-looking statements, including, without limitation, statements containing the words "believes," "anticipates," "expects," "intends," "plans," "seeks," "estimates," "may," "will," "could," "stands to," and "continues," as well as similar expressions. Such forward-looking statements may involve known and unknown risks, uncertainties and other factors which might cause the actual results, financial condition, performance or achievements of Galapagos, or industry results, to be materially different from*

The logo for Galapagos, featuring the word "Galapagos" in a dark teal, sans-serif font.The logo for BioFocus DPI, with "BioFocus" in dark teal and "DPI" in orange. Below it, the text "A Galapagos Company" is written in a smaller, dark teal font. A thin, light grey curved line arches over the text on the right side.

*any historic or future results, financial conditions, performance or achievements expressed or implied by such forward-looking statements. Given these uncertainties, the reader is advised not to place any undue reliance on such forward-looking statements. These forward-looking statements speak only as of the date of publication of this document. Galapagos expressly disclaims any obligation to update any such forward-looking statements in this document to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based, unless required by law or regulation.*